Immutep’s Efti Shows Promising Results in Head and Neck Cancer Trial

Immutep Ltd ( (AU:IMM) ) just unveiled an update.

Immutep Limited announced promising results from its Phase IIb trial of eftilagimod alfa (efti) in combination with KEYTRUDA® for head and neck cancer patients with PD-L1 CPS <1. The trial demonstrated a median overall survival of 17.6 months, significantly surpassing current standard treatments. This combination therapy addresses a high unmet need for patients with no available chemotherapy-free options, showing potential for regulatory approval discussions with the FDA. The safety profile remains favorable, and the company plans to continue data analysis and regulatory discussions.

More about Immutep Ltd

Immutep Limited is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a pioneer in the field of Lymphocyte Activation Gene-3 (LAG-3) therapeutics, aiming to stimulate or suppress the immune response. Immutep’s product portfolio includes treatments for various solid tumors, such as non-small cell lung cancer, head and neck squamous cell carcinoma, and metastatic breast cancer.

YTD Price Performance: -10.31%

Average Trading Volume: 5,000

Technical Sentiment Signal: Strong Buy

Current Market Cap: $254.2M

For detailed information about IMM stock, go to TipRanks’ Stock Analysis page.